Last reviewed · How we verify
TAC chemotherapy
TAC chemotherapy is a Chemotherapy regimen (combination) Small molecule drug developed by Agendia. It is currently FDA-approved for Breast cancer (neoadjuvant and adjuvant treatment), Node-positive breast cancer.
TAC is a chemotherapy regimen combining docetaxel, doxorubicin, and cyclophosphamide to kill rapidly dividing cancer cells through multiple cytotoxic mechanisms.
TAC chemotherapy is not a verified fact, as the provided information does not mention a combination of chemotherapy drugs called TAC. However, based on the information, Decitabine is a small molecule (ChEMBL) used to treat conditions such as Recurrent Acute Myeloid Leukemia (ClinicalTrials.gov).
At a glance
| Generic name | TAC chemotherapy |
|---|---|
| Sponsor | Agendia |
| Drug class | Chemotherapy regimen (combination) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
TAC delivers three chemotherapy agents that work synergistically: docetaxel (a taxane microtubule stabilizer), doxorubicin (a topoisomerase II inhibitor and DNA intercalator), and cyclophosphamide (an alkylating agent). Together they disrupt cell division, damage DNA, and induce apoptosis in cancer cells. This combination is typically used as neoadjuvant or adjuvant therapy in breast cancer to improve pathologic complete response and survival outcomes.
Approved indications
- Breast cancer (neoadjuvant and adjuvant treatment)
- Node-positive breast cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Mucositis
- Alopecia
- Fatigue
- Peripheral neuropathy
- Cardiotoxicity
- Infection
Key clinical trials
- A Norwegian Trial Comparing Treatment Strategies for Carpal Tunnel Syndrome (PHASE4)
- Bladder Directed vs. Pelvic Floor Therapy in IC/BPS (PHASE2)
- Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy (PHASE2)
- Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy (PHASE2)
- Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients (PHASE2, PHASE3)
- Triple Therapy Strategy for Managing Persistent Pain After Spinal Microdiscectomy (PHASE2)
- A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors. (PHASE2)
- Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAC chemotherapy CI brief — competitive landscape report
- TAC chemotherapy updates RSS · CI watch RSS
- Agendia portfolio CI
Frequently asked questions about TAC chemotherapy
What is TAC chemotherapy?
How does TAC chemotherapy work?
What is TAC chemotherapy used for?
Who makes TAC chemotherapy?
What drug class is TAC chemotherapy in?
What development phase is TAC chemotherapy in?
What are the side effects of TAC chemotherapy?
Related
- Drug class: All Chemotherapy regimen (combination) drugs
- Manufacturer: Agendia — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Breast cancer (neoadjuvant and adjuvant treatment)
- Indication: Drugs for Node-positive breast cancer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing